- Home
- CNTB vs ATYR Comparison
CNTB vs ATYR Comparison
Compare CNTB & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- ATYR
- Stock Information
- Founded
- CNTB 2012
- ATYR 2005
- Country
- CNTB United States
- ATYR United States
- Employees
- CNTB N/A
- ATYR N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTB Health Care
- ATYR Health Care
- Exchange
- CNTB Nasdaq
- ATYR Nasdaq
- Market Cap
- CNTB 94.2M
- ATYR 105.8M
- IPO Year
- CNTB 2021
- ATYR 2015
- Fundamental
- Price
- CNTB $1.59
- ATYR $0.96
- Analyst Decision
- CNTB Strong Buy
- ATYR Buy
- Analyst Count
- CNTB 2
- ATYR 6
- Target Price
- CNTB $7.50
- ATYR $8.88
- AVG Volume (30 Days)
- CNTB 79.5K
- ATYR 8.3M
- Earning Date
- CNTB 11-30-2025
- ATYR 11-11-2025
- Dividend Yield
- CNTB N/A
- ATYR N/A
- EPS Growth
- CNTB N/A
- ATYR N/A
- EPS
- CNTB N/A
- ATYR N/A
- Revenue
- CNTB $1,965,000.00
- ATYR N/A
- Revenue This Year
- CNTB N/A
- ATYR $420.85
- Revenue Next Year
- CNTB $453,067.90
- ATYR $1,513.40
- P/E Ratio
- CNTB N/A
- ATYR N/A
- Revenue Growth
- CNTB N/A
- ATYR N/A
- 52 Week Low
- CNTB $1.23
- ATYR $0.68
- 52 Week High
- CNTB $2.20
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- CNTB 45.14
- ATYR 32.21
- Support Level
- CNTB $1.50
- ATYR $0.94
- Resistance Level
- CNTB $1.72
- ATYR $1.02
- Average True Range (ATR)
- CNTB 0.13
- ATYR 0.08
- MACD
- CNTB -0.02
- ATYR 0.12
- Stochastic Oscillator
- CNTB 18.00
- ATYR 32.23
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.